ArticleMovement disorders clinical practice2026
Efficacy and Safety of the Felix NeuroAI Wristband for Essential Tremor: Results of a 1-Year Open-Label Extension Trial.
Article in Movement disorders clinical practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundEssential tremor (ET) impacts daily activities and quality of life. A pivotal study of a transcutaneous peripheral nerve stimulation (TPNS) device, the Felix NeuroAI Wristband, led to Food and Drug Administration (FDA) clearance in 2025.
objectiveThe aim of the study was to report 1-year follow-up results.
methodsPatients who completed the 90-day randomized phase could continue until 1 year after the baseline visit; those in the sham group were crossed over to active TPNS treatment (delayed-start TPNS). Outcome measures were assessed at 180 days and 1 year: modified Activities of Daily Living (mADL) subscale of TETRAS, Clinical and Patient Global Impression of Improvement (CGI-I and PGI-I), Quality of Life in Essential Tremor Questionnaire, and adverse device effects (ADEs).
resultsOf 93 patients who entered the extension phase (58 TPNS and 35 delayed start), 57 (38 and 19, respectively) completed 1 year of follow-up. In the TPNS group, mADL improvement increased from 6.9 points at day 90 to 9.7 points at 1 year. Ninety days of active treatment improved mADL scores by 5.5 points in the delayed-start TPNS group (day 180). From baseline, TETRAS ADL scores in the TPNS group improved by 6.1 ± 6.0 points at 90 days and 9.3 ± 6.0 points at 1 year. CGI-I, PGI-I, and quality of life improved in both groups from 90 days to 1 year. Twenty-three new ADEs occurred (mild skin irritation, n = 22; muscle spasms, n = 1).
conclusionsTPNS use was associated with sustained functional improvement for up to 1 year with acceptable safety. Patients who initiated active therapy earlier demonstrated greater cumulative benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.